$0.09
(Market cap
$11 Mln
Recently Viewed
Clear AllMarket cap
$11 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-11.7
Debt to Equity
0
Book Value
$--
EPS
$-6.7
Face value
--
Shares outstanding
7,540,734
CFO
$-75.47 Mln
EBITDA
$-218.20 Mln
Net Profit
$-232.43 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biovie Inc (BIVI)
| 37.1 | 16.9 | 29.3 | -81.1 | -86.9 | -76.4 | -51.3 |
|
BSE Sensex*
| -9.2 | 4.5 | -6.1 | -2.9 | 8.2 | 9.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Biovie Inc (BIVI)
| -94.2 | -83.9 | -83.8 | 72.7 | -74.0 | 394.9 | -0.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biovie Inc (BIVI)
|
1.6 | 11.3 | 0.0 | -17.4 | -- | -91.1 | -- | 0.6 |
| 73.6 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 226.7 | 14,164.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 61.6 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.7 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 88.5 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 520.1 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 421.4 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 104.0 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 331.0 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment... of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. Read more
President, CEO & Director
Mr. Cuong Viet Do M.B.A.
President, CEO & Director
Mr. Cuong Viet Do M.B.A.
Headquarters
Carson City, NV
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Biovie Inc (BIVI) is $1.59 (NASDAQ) as of 27-Apr-2026 16:00 EDT. Biovie Inc (BIVI) has given a return of -86.86% in the last 3 years.
Since, TTM earnings of Biovie Inc (BIVI) is negative, P/E ratio is not available.
The P/B ratio of Biovie Inc (BIVI) is 0.59 times as on 24-Apr-2026, a 87 discount to its peers’ median range of 4.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.05
|
0.05
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Biovie Inc (BIVI) are Rs 13.20 and Rs 1.06 as of 28-Apr-2026.
Biovie Inc (BIVI) has a market capitalisation of $ 11 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Biovie Inc (BIVI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.